Dendritic Cell (DC) and Tumor-Specific Cytotoxic T Cell (CTL) Generation Protocol from Healthy Volunteers and Patients with Malignant Brain Tumors


The purpose of this project is to perform a series of studies aimed at developing a dendritic cell-based vaccine for patients with malignant brain tumors. In preparation for a Phase I clinical trial, we wish to validate our ability: (1) To generate and phenotypically and functionally characterize large numbers of DCs generated from patients with malignant brain tumors; (2) To optimize the efficiency of transfection of DCs with tumor RNA, and; (3) To generate cytotoxic T lymphocyte reactivity to the tumor-specific antigens with these DCs.


Brain Tumors, Glioblastoma multiforme, Metastatic brain tumor, Glioma

Principal Investigator

Duane A Mitchell, M.D.



Contact Information

(352) 273-9000

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams